- Home
- OKYO vs BNR Comparison
OKYO vs BNR Comparison
Compare OKYO & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- BNR
- Stock Information
- Founded
- OKYO 2007
- BNR 2014
- Country
- OKYO United Kingdom
- BNR China
- Employees
- OKYO N/A
- BNR N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- BNR Medical Specialities
- Sector
- OKYO Health Care
- BNR Health Care
- Exchange
- OKYO Nasdaq
- BNR Nasdaq
- Market Cap
- OKYO 37.0M
- BNR 30.9M
- IPO Year
- OKYO 2022
- BNR 2020
- Fundamental
- Price
- OKYO $1.50
- BNR $2.94
- Analyst Decision
- OKYO Strong Buy
- BNR
- Analyst Count
- OKYO 1
- BNR 0
- Target Price
- OKYO $7.00
- BNR N/A
- AVG Volume (30 Days)
- OKYO 58.3K
- BNR 20.3K
- Earning Date
- OKYO 05-06-2025
- BNR 05-28-2025
- Dividend Yield
- OKYO N/A
- BNR N/A
- EPS Growth
- OKYO N/A
- BNR N/A
- EPS
- OKYO N/A
- BNR N/A
- Revenue
- OKYO N/A
- BNR $70,669,261.00
- Revenue This Year
- OKYO N/A
- BNR $136.32
- Revenue Next Year
- OKYO N/A
- BNR N/A
- P/E Ratio
- OKYO N/A
- BNR N/A
- Revenue Growth
- OKYO N/A
- BNR N/A
- 52 Week Low
- OKYO $0.81
- BNR $2.62
- 52 Week High
- OKYO $1.74
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- OKYO 65.97
- BNR 24.38
- Support Level
- OKYO $1.03
- BNR $2.77
- Resistance Level
- OKYO $1.24
- BNR $3.29
- Average True Range (ATR)
- OKYO 0.11
- BNR 0.30
- MACD
- OKYO 0.03
- BNR 0.01
- Stochastic Oscillator
- OKYO 70.12
- BNR 13.82
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.